Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer

Clinical Breast Cancer

Volumn 12, Issue 2, 2012, Pages 87-93

  Schwartzberg, Lee S ^a   Arena, Francis P ^b   Mintzer, David M ^c   Epperson, Amanda L ^d   Walker, Mark S ^d  

^a WEST CLINIC   (United States)

^b Arena Oncology Associates   (United States)

^c Pennsylvania Oncology Hematology Associates   (United States)

^d Accelerated Community Oncology Research Network   (United States)

Author keywords

Antimetabolite; Chemotherapy; Combination therapy; HER2 negative; Taxane

Indexed keywords

ALBUMIN; ALBUMIN BOUND PACLITAXEL; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRACHIAL PLEXUS INJURY; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; EDEMA; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOVOLEMIA; INSOMNIA; LUNG EMBOLISM; MENTAL FUNCTION; METASTASIS; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84858965929     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.10.004     Document Type: Article

References (27)

1. American Cancer Society. Breast Cancer. Available at: http://www.cancer.org/Cancer/BreastCancer/index. Accessed: June 27, 2011.
2. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
3. Winer E, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 2004; 22:2081-68.
4. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B 9840. J Clin Oncol 2008; 28:1642-9.
5. Xeloda [package insert]; San Francisco, CA: Genentech USA, Inc; February 2011.
6. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-72. (Pubitemid 34548055)
7. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-54. (Pubitemid 32994752)
8. Ishikawa T, Utoh N, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new fluoropyrimidine carbamate in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-7. (Pubitemid 28167730)
9. Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004; 22:2321-7. (Pubitemid 41115388)
10. Blum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 27:4384-90. (Pubitemid 46630975)
11. Abraxane [prescribing information]; Bridgewater, NJ: Abraxis BioScience, LLC; March 2010.
12. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803. (Pubitemid 46657376)
13. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7:850-6.
14. Gradishar WJ, Krasnohon D, Cheporov S, et al. Significantly longer progressionfree survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-9.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16. (Pubitemid 30099779)
16. National Cancer Institute: Biometric Research Branch, Division of Cancer Treatment and Diagnosis. Optimal Two-Stage Phase II Design Software. Available at: http://linus.nci.nih.gov/~brb/Opt.htm. Accessed: November 1, 2011.
17. National Cancer Institute: Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Available at: http://ctep.cancer.gov/. Accessed: November 1, 2011.
18. Blum JL, Dees EC, Vukelja SJ, et al. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every 3 week taxane therapy. Clin Breast Cancer 2007; 7:465-70. (Pubitemid 46424283)
19. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004; 9(suppl 2):24-32. (Pubitemid 38747840)
20. Carlson RW, Allred DC, Anderson BO, et al. NCCN Clinical Practice guidelines in oncology: breast cancer. Version 2.2011. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed: November 1, 2011.
21. Albain KS, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel vs. paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26:3950-7.
22. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10:553-60. (Pubitemid 29305433)
23. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23. (Pubitemid 34651510)
24. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
25. Roy V, LaPlant BR, Gross GG, et al. Phase II trial of weekly nab (nanoparticle albumin bound)-paclitaxel (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009; 20:449-53.
26. Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res 2010; 123:427-35.
27. Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin bound-paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010; 10:281-7.